Effect of Smoking Cessation on Salivary IL-1β and PGE-2 Levels Following Non-Surgical Periodontal Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06145685

Enrollment

Registered

2023-11-24

Start date

2021-01-01

Completion date

2022-02-28

Last updated

2023-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases, Smoking Cessation

Keywords

Smoking Cessation, Periodontal Diseases, Inflammatory Markers, Interleukin-1beta, Prostaglandin E2, Non-surgical therapy, Smoking

Brief summary

The aim of this study is to evaluate the effect of smoking cessation on inflammatory markers following non-surgical treatment of periodontal disease. This is to assess the period of smoking abstinence needed before any periodontal surgery in order to reverse the negative effects of the reported increased levels of inflammatory markers (IL-1β and PGE2 in this study) associated with smoking on the healing and the periodontium.

Interventions

PROCEDUREMinimally invasive non-surgical periodontal therapy

Minimally invasive non-surgical periodontal therapy

PROCEDUREConventional non-surgical periodontal therapy

Conventional non-surgical periodontal therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Caregiver)

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with advanced chronic periodontitis upon clinical examination with clinical attachment loss (CAL) more than 5 mm. * Patients willing to quit smoking to be included in two groups, while patients unwilling to quit smoking to be included in the third group, and the non-smokers as the fourth group.

Exclusion criteria

* Any systemic illness known to affect the outcome. * Systemic antimicrobial or anti-inflammatory drug therapy within the last 3 months prior to the study. * Patients unable to perform routine oral hygiene procedures. * Patients using other forms of tobacco.

Design outcomes

Primary

Measure	Time frame	Description
Levels of Prostaglandin E2	Baseline and 2 months	Salivary biochemical analysis
Interleukin 1 beta (in PG/ml)	Baseline and 2 months	Salivary biochemical analysis

Secondary

Measure	Time frame	Description
bone gain (in mm)	Baseline and 9 months	Periodontal clinical parameter
Pocket depth (in mm)	Baseline and 9 months	Periodontal clinical parameter
Periodontal clinical parameters	Baseline and 9 months	Gingival index (scores)
Plaque index (scores)	Baseline and 9 months	Periodontal clinical parameters
clinical attachment level (in mm)	Baseline and 9 months	Periodontal clinical parameter

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026